Business
‘Not for the faint-hearted’: COVID crisis brings boom time for biotechs – Sydney Morning Herald
The pandemic has put the focus on Australia’s biotech sector where high risk, high reward is par for the course and regulators can make or break a company.
Normal text sizeLarger text sizeVery large text size
Mesoblast boss and major shareholder Silviu Itescu wont be the only one breathing easier now that the ASX-listed biotechs flagship treatment has managed to get the green light from the US regulators advisory committee.
It was a close run thing by all accounts and for Itescu and investors in Mesoblast a no vote would have seen a decades worth of work come to a standstill.
For his part, Itescu says he wasnt quite as spooked as investors by si…
-
Business19 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News18 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General13 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News15 hours agoTips to improve engagement – Proctor